 WOBURN, Mass., March 04, 2021 GLOBE NEWSWIRE -- Replimune Group, Inc. Nasdaq: REPL, a biotechnology company developing oncolytic immuno-gene therapies derived from its ImmulyticTM platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. 